Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC
Combination treatment of regorafenib and oral methotrexate in patients with <i>KRAS</i>-mutant NSCLC was limited due to toxicity, and the study did not meet its primary end point. Computational modeling may aid in repurposing therapeutic options though caution must be exercised with tolerability.
Authors
- Maximilian Diehn (ORCID: https://orcid.org/0000-0003-2032-0581)
- Gerald J. Berry (ORCID: https://orcid.org/0000-0002-6176-2629)
- Kavitha Ramchandran (ORCID: https://orcid.org/0000-0002-9033-819X)
- Joel W. Neal (ORCID: https://orcid.org/0000-0003-3119-9334)
- Heather A. Wakelee (ORCID: https://orcid.org/0000-0003-1136-980X)
- Vivian W. L. Tsang (ORCID: https://orcid.org/0000-0001-9401-008X)
- Grace Hwang (ORCID: https://orcid.org/0000-0001-7730-6516)
- Sukhmani K. Padda (ORCID: https://orcid.org/0000-0002-8691-7754)
- Ameen Abdulla Salahudeen (ORCID: https://orcid.org/0000-0001-9037-3481)
- Angela B. Hui (ORCID: https://orcid.org/0000-0002-5471-1428)
- Kristen May Cunanan (ORCID: https://orcid.org/0000-0001-9873-9214)
- Jacqueline V. Aredo (ORCID: https://orcid.org/0000-0003-0559-3565)
- Brittany Johnson
- Bernice Y. Kwong
- H. Henry Guo (ORCID: https://orcid.org/0000-0001-5511-1750)
- Isabelle Blanchard
- Matthew J. Loza (ORCID: https://orcid.org/0000-0002-8609-118X)
- Shireen Vali
- Danny Pancirer
Institutions
- Fox Chase Cancer Center (US)
- University of Illinois Chicago (US)
- Cellworks Research (India) (IN)
- Temple University Health System (US)
- Stanford University (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100741
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Bayer Corporation